Service of General Internal Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland; Service of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, 4, rue Gabrielle Perret-Gentil, 1211 Geneva 14, Switzerland.
Service of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, 4, rue Gabrielle Perret-Gentil, 1211 Geneva 14, Switzerland; Service of Diabetology and Endocrinology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Int J Infect Dis. 2017 Jun;59:61-64. doi: 10.1016/j.ijid.2017.04.012. Epub 2017 Apr 24.
After antibiotic therapy of an initial diabetic foot infection (DFI), pathogens isolated from subsequent episodes might become more resistant to commonly prescribed antibiotics. If so, this might require a modification of the current recommendations for the selection of empiric antibiotic therapy. This study investigated whether the Infectious Diseases Society of America (IDSA) DFI guideline recommendations should be modified based on the number of past DFI episodes.
This was a single-centre retrospective cohort survey of DFI patients seen during the years 2010 to 2016.
A total 1018 episodes of DFI in 482 adult patients were identified. These patients were followed-up for a median of 3.3 years after the first DFI episode. The total number of episodes was 2257 and the median interval between recurrent episodes was 7.6 months. Among the recurrent DFIs, the causative pathogens were the same as in the previous episode in only 43% of cases (158/365). Staphylococcus aureus was the predominant pathogen in all episodes (range 1 to 13 episodes) and was not more prevalent with the increasing number of episodes. DFIs were treated with systemic antibiotics for a median duration of 20 days (interquartile range 11-35 days). Overall, there was no significant increase in the incidence of antibiotic resistance to methicillin, rifampicin, clindamycin, or ciprofloxacin over the episodes (Pearson's Chi-square test p-values of 0.76, 1.00, 0.06, and 0.46, respectively; corresponding p-values for trend of 0.21, 0.27, 0.38, and 0.08, respectively).
After the successful treatment of a DFI, recurrent episodes are frequent. A history of a previous DFI episode did not predict a greater likelihood of any antibiotic-resistant isolate in subsequent episodes. Thus, broadening the spectrum of empiric antibiotic therapy for recurrent episodes of DFI does not appear necessary.
在初始糖尿病足感染(DFI)的抗生素治疗后,从后续发作中分离出的病原体可能对常用处方抗生素的耐药性增加。如果是这样,这可能需要修改当前针对经验性抗生素治疗选择的建议。本研究调查了根据过去 DFI 发作次数,是否应修改美国传染病学会(IDSA)DFI 指南建议。
这是一项对 2010 年至 2016 年期间就诊的 DFI 患者进行的单中心回顾性队列调查。
共确定了 482 例成年患者的 1018 例 DFI 发作。这些患者在首次 DFI 发作后中位数随访 3.3 年。总发作次数为 2257 次,复发间隔中位数为 7.6 个月。在复发性 DFI 中,只有 43%(158/365)的情况下,病原体与前一次发作相同。金黄色葡萄球菌是所有发作中的主要病原体(范围 1 至 13 次发作),且随着发作次数的增加,其并不更为普遍。DFI 接受全身抗生素治疗的中位数持续时间为 20 天(四分位间距 11-35 天)。总体而言,在发作过程中,对甲氧西林、利福平、克林霉素或环丙沙星的抗生素耐药性发生率没有明显增加(皮尔逊卡方检验的 p 值分别为 0.76、1.00、0.06 和 0.46,相应的趋势 p 值分别为 0.21、0.27、0.38 和 0.08)。
DFI 成功治疗后,复发发作频繁。先前 DFI 发作的病史并不能预测随后发作中出现任何抗生素耐药分离株的可能性更大。因此,对于 DFI 复发性发作,扩大经验性抗生素治疗的范围似乎没有必要。